Progressive supranuclear palsy: where are we now? (Q30810295)

26 June 2017

1 reference

title

Progressive supranuclear palsy: where are we now? (English)

1 reference

progressive supranuclear palsy

26 June 2017

main subject

1 reference

Andrew J Lees

1 reference

26 June 2017

0 references

David J Burn

1 reference

26 June 2017

publication date

1 October 2002

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

page(s)

359-369

1 reference

Did Charles Dickens describe progressive supranuclear palsy in 1857?

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

An early photographic case of probable progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Prevalence and natural history of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Prevalence of Parkinson's disease in the elderly: The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

High prevalence of Parkinson's disease in the Faroe Islands

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Can a neuropsychological follow up contribute to the diagnosis of parkinsonian syndromes?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

1 reference

7 January 2021

Dystonia in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Arm levitation in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

A case of spontaneous arm levitation in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Progressive supranuclear palsy with palatal myoclonus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Whipple's disease mimicking progressive supranuclear palsy: the diagnostic value of eye movement recording

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Neurosyphilis presenting as progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Research goals in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Lipoperoxidation is selectively involved in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Differentiation of atypical parkinsonian syndromes with routine MRI

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Abnormal signals on proton density-weighted MRI of the superior cerebellar peduncle in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Apparent diffusion coefficient measurements in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Functional imaging in relation to parkinsonian syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

PET measures of benzodiazepine receptors in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Cholinergic vesicular transporters in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Can imaging distinguish PSP from other neurodegenerative disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Neurophysiological characterization of parkinsonian syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Sphincter EMG and differential diagnosis of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Neuronal loss in Onuf's nucleus in three patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

The auditory startle reaction in parkinsonian disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Somatosensory evoked potentials in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Distinctive abnormalities of facial reflexes in patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Progressive supranuclear palsy in the molecular age

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

New insights into progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Familial progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Familial progressive supranuclear palsy. Description of a pedigree and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Autopsy-proven progressive supranuclear palsy in two siblings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Clinical genetics of familial progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Performance on the PD test battery by relatives of patients with progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Tau protein pathology in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

The molecular genetics of the tauopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

"Missing" tau mutation identified

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Progressive supranuclear palsy as a disease phenotype caused by the S305S tau gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Sequence analysis of tau in familial and sporadic progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Genetic evidence for the involvement of tau in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Association of an extended haplotype in the tau gene with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Tau genotype: no effect on onset, symptom severity, or survival in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

The tau A0 allele in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Case-control study of the extended tau gene haplotype in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Tau and Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

1 reference

7 January 2021

Progressive Supranuclear Palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Pharmacological Therapy in Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Retrospective study of drug response in 87 patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Result of Long-Term Administration of L-Threo-3,4-Dihydroxyphenylserine in Patients With Pure Akinesia as an Early Symptom of Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Pramipexole in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Zolpidem in Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Zolpidem in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Donepezil in the treatment of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900161-8

7 January 2021

10.1016/S1474-4422(02)00161-8

Identifiers

DOI

1 reference

26 June 2017

1 reference